A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer
NCT04975061
·
clinicaltrials.gov ↗
UNKNOWN
Status
58
Enrollment
INDUSTRY
Sponsor class
Conditions
Effectiveness，Safety，Thymic Cancer
Interventions
DRUG:
YY-20394
Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.